Tiotropium in Children and Adolescents With Asthma

Asthma is a major cause of morbidity in children, despite the availability of various treatments. In adults, tiotropium —a long-acting muscarinic antagonist (LAMA)—as add-on therapy to an inhaled corticosteroid (ICS) with or without a long-acting β2-agonist provides clinical benefit with a safety profile similar to placebo. Objective: To review published evidence on the efficacy and safety of tiotropium as add-o n LAMA therapy in children and adolescents with asthma that is uncontrolled despite use of an ICS with or without additional controller medication(s).
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research